Correlation Between Clinical Nodal Status and Sentinel Lymph Node Biopsy False Negative Rate After Neoadjuvant Chemotherapy

详细信息    查看全文

• 作者：Maiko Takahashi (1)
  Hiromitsu Jinno (1)
  Tetsu Hayashida (1)
  Michio Sakata (1)
  Keiko Asakura (2)
  Yuko Kitagawa (1)
  
• 刊名：World Journal of Surgery
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：36
• 期：12
• 页码：2847-2852
• 全文大小：179KB
• 参考文献：1. Fisher B, Jeong JH, Anderson S et al (2002) Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347:567-75 CrossRef
  2. Orr RK (1999) The impact of prophylactic axillary node dissection on breast cancer survival—a Bayesian meta-analysis. Ann Surg Oncol 6:109-16 CrossRef
  3. Giuliano AE, Kirgan DM, Guenther JM et al (1994) Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220:391-98 discussion 398-01 CrossRef
  4. Albertini JJ, Lyman GH, Cox C et al (1996) Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 276:1818-822 CrossRef
  5. Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-685
  6. Bonadonna G, Veronesi U, Brambilla C et al (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539-545 CrossRef
  7. Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483-493
  8. Fisher B, Mamounas EP (1995) Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol 13:537-40
  9. Kuerer HM, Newman LA (2005) Lymphatic mapping and sentinel lymph node biopsy for breast cancer: developments and resolving controversies. J Clin Oncol 23:1698-705 CrossRef
  10. Schwartz GF, Hortobagyi GN (2003) Committee CC proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast. April 26-8, 2003, Philadelphia, Pennsylvania. Cancer 100:2512-532 CrossRef
  11. Sharkey FE, Addington SL, Fowler LJ et al (1996) Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma. Mod Pathol 9:893-00
  12. Fisher ER, Wang J, Bryant J et al (2002) Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-18. Cancer 95:681-95 CrossRef
  13. Mamounas EP, Brown A, Anderson S et al (2005) Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23:2694-702 CrossRef
  14. Xing Y, Foy M, Cox DD et al (2006) Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg 93:539-46 CrossRef
  15. Kuerer HM, Sahin AA, Hunt KK et al (1999) Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230:72-8 CrossRef
  16. Fraile M, Rull M, Julian FJ et al (2000) Sentinel node biopsy as a practical alternative to axillary lymph node dissection in breast cancer patients: an approach to its validity. Ann Oncol 11:701-05 CrossRef
  17. Miltenburg DM, Miller C, Karamlou TB et al (1999) Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res 84:138-42 CrossRef
  18. Kim T, Giuliano AE, Lyman GH (2006) Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 106:4-6 CrossRef
  19. Le Bouedec G, Gauthier T, Gimbergues P et al (2008) Axillary recurrence after negative sentinel lymph node biopsy in breast cancer. Presse Med 37:1685-687 CrossRef
  20. Tausch C, Konstantiniuk P, Kugler F et al (2006) Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian sentinel node study Group. Ann Surg Oncol 15:3378-383 CrossRef
  21. Shen J, Gilcrease MZ, Babiera GV et al (2007) Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer 109:1255-263 CrossRef
  22. Lee S, Kim EY, Kang SH et al (2007) Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients. Breast Cancer Res Treat 102:283-88 CrossRef
  23. Kinoshita T, Takasugi M, Iwamoto E et al (2006) Sentinel lymph node biopsy examination for breast cancer patients with clinically negative axillary lymph nodes after neoadjuvant chemotherapy. Am J Surg 191:225-29 CrossRef
  
• 作者单位：Maiko Takahashi (1)
  Hiromitsu Jinno (1)
  Tetsu Hayashida (1)
  Michio Sakata (1)
  Keiko Asakura (2)
  Yuko Kitagawa (1)
  
  1. Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo, 160-8587, Japan
  2. Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan
  
• ISSN：1432-2323

文摘

Background Neoadjuvant chemotherapy (NAC) is the standard treatment for locally advanced breast cancer. It is now being used to treat operable breast cancer to facilitate breast-conserving surgery, but the accuracy of sentinel lymph node biopsy (SLNB) in breast cancer patients receiving NAC remains open to considerable debate. Methods We enrolled 96 patients with stage II–III breast cancer who received NAC from January 2001 to July 2010. All patients underwent breast surgery and SLNB, followed immediately by complete axillary lymph node dissection (ALND). Sentinel lymph nodes were detected with blue dye and radiocolloid injected intradermally just above the tumor and then evaluated with hematoxylin and eosin and immunohistochemical staining. Results The overall identification rate for SLNB was 87.5?% (84/96); the false negative rate (FNR) was 24.5?% (12/49); and the accuracy rate was 85.7?% (72/84). The FNR was significantly lower in clinically node-negative patients than in node-positive patients before NAC (5.5?% vs. 35.5?%; p?=?0.001). Accuracy was also significantly higher in clinically node-negative patients than in node-positive patients before NAC (97.2?% vs. 77.1?%; p?=?0.009). The FNR was 27.3?% among 46 clinically node-positive patients before NAC who were clinically node-negative after NAC. Among 12 patients with a complete tumor response (CR), the FNR was 0?%, compared with 26.1?% for 83 patients with a partial response and stable disease (p?=?0.404). Conclusions Although associated with a high FNR after NAC, SLNB would have successfully replaced ALND in clinically node-negative patients before NAC and in patients with a CR after NAC.